Dr. Gooderham, discusses using systemic Janus kinase (JAK) inhibitors like upadacitinib in patients with atopic dermatitis. She reviews appropriate indications for patient selection with JAK inhibitors for atopic dermatitis and best practices for monitoring potential adverse events such as cytopenias, lipid elevations, headaches, acne, signs of infection, herpes zoster, and symptoms suggestive of venous thromboembolism. In addition, Dr. Gooderham gives recommendations for prescribing JAK inhibitors, as well as tips for managing potential adverse reactions and navigating various other scenarios in the clinic.
Topics Covered:
- Indications for patient selection and monitoring with JAK inhibitors for atopic dermatitis
- Recommendations for prescribing JAK inhibitors
- Managing potential adverse events
